Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial. - Cassidy, J.; Douillard, J.-Y.; Twelves, C.; McKendrick, J. J.; Scheithauer, W.; Bustová, I.; Johnston, P. G.; Lesniewski-Kmak, K.; Jelic, S.; Fountzilas, G.; Coxon, F.; Díaz-Rubio, E.; et al. (British Journal of Cancer, 2006)